CD19 or CD20 CAR T cells briging HSCT
Southwest Hospital，China
Phase 2 mab active
Quick answer
CD19 or CD20 CAR T cells briging HSCT for Lymphoma, Large B-Cell, Diffuse is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Lymphoma, Large B-Cell, Diffuse
- Phase
- Phase 2
- Modality
- mab
- Status
- active